Shark cartilage monograph: A clinical decision support tool

Journal of Herbal Pharmacotherapy

Volumn 2, Issue 2, 2002, Pages 71-93

  Hammerness, Paul ^a   Berrette, Ernie Paul ^a   Szapary, Philippe ^a   Smith, Michael ^a   Bent, Steve ^a   Ulbricht, Catherine ^a   Boon, Heather ^a   Sollars, David ^a   Tsouronis, Candy ^a   Basch, Ethan ^a  

^a Natural Standard   (United States)

Author keywords

AE 941; Cartilage; Haifischknorpel; Houtsmuller diet; Shark cartilage; Squalamine; U 955

Indexed keywords

AE 941; ALPHA INTERFERON; AMINOTRIAZOLE; ANGIOGENESIS INHIBITOR; ANTIDIABETIC AGENT; BEFEFIN; BETA INTERFERON; CALCIUM; CARTILADE; CGS 27023A; CHONDROITIN SULFATE; CILENGITIDE; CISPLATIN; CM 101; FUMAGILLOL CHLOROACETYLCARBAMATE; GLUCOSAMINE SULFATE; GLYCOPROTEIN; INTERLEUKIN 12; KERATAN SULFATE; LEFLUNOMIDE; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; PRINOMASTAT; SEMAXANIB; SHARK CARTILAGE EXTRACT; TANOMASTAT; THALIDOMIDE; THIAZIDE DIURETIC AGENT; TISSUE EXTRACT; TROPONIN I; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ALLERGY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARTILAGE; CONTROLLED STUDY; DRUG ANALYSIS; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; MEDICAL DECISION MAKING; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SHARK;

EID: 18344370042     PISSN: 15228940     EISSN: None     Source Type: Journal    
DOI: 10.1300/J157v02n02_08     Document Type: Article

References (62)

1. Neovastat®: An inhibitor of angiogenesis with anti-cancer activity
2. Phase I/II lung cancer clinical trial results with AE-941 (Neovastat®) an inhibitor of angiogenesis
3. Inhibition of tumor angiogenesis mediated by cartilage
4. Current status of antiangiogenic factors
5. Two phase II studies of oral dry shark cartilage powder (SCP) in patients with either metastatic breast or prostate cancer refractory to standard treatment
6. Shark cartilage and neutraceutical update
7. High rate of bioactivity (reduction in gross tumor size) observed in advance cancer patients treated with shark cartilage material
8. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer
9. AE-941 (Neovastat®), an inhibitor of angiogenesis: Phase I/II cancer clinical trial results
10. A guide to the use of shark cartilage in the treatment of arthritis and other inflammatory joint diseases
11. Shark cartilage for cancer treatment
12. Topical shark cartilage subdues psoriasis
13. Previous Human Experience-Cuban Clinical Trials
14. Antiangiogenic properties of a novel shark cartilage extract: Potential role in the treatment of psoriasis
15. Alternative therapies for the treatment of childhood cancer
16. Oral shark cartilage in the treatment of patients with advanced primary brain tumors. A phase II pilot study
17. Phase I/II trial on AE-941 (Neovastat®) in patients with metastatic refractory prostate cancer
18. Shark cartilage-induced hepatitis
19. AE-941, an inhibitor of angiogenesis: Rational for development in combination with induction chemotherapy/radiotherapy in-patients with non-small-cell lung cancer (NSCLC)
20. Immunomodulation by thalidomide and thalidomide analogues
21. Effect of AE-941 (Neovastat®), an angiogenesis inhibitor, in the Lewis lung carcinoma metastatic model, efficacy, toxicity prevention and survival
22. Troponin I is present in human cartilage and inhibits angiogenesis
23. Demonstration of immunogenic keratan sulphate in commercial chondroitin 6-sulphate from shark cartilage. Implications for ELISA assays
24. Shark cartilage contains inhibitors of tumor angiogenesis
25. Identification of an inhibitor of neo-vascularization from cartilage
26. Inhibition of neovascularization by a cartilage factor
27. Isolations of a cartilage factor that inhibits tumor neovascularization
28. Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium
29. A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis
30. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on antiangiogenesis and anti-tumor activities
31. Shark cartilage extract interferes with cell adhesion and induces reorganization of focal adhesions in cultured endothelial cells
32. A cartilage-derived inhibitor of neovascularization and metal-loproteinases
33. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound
34. Antiangiogenic effects of the oral administration of liquid cartilage extract in humans
35. Primary structure of a protein isolated from reef shark (Carcharhinus springeri) cartilage that is similar to the mammalian C-type lectin homolog, tetranectin
36. The role of angiogenesis in rheumatoid arthritis: Recent developments
37. AE-941, a novel inhibitor of angiogenesis has significant anti-inflammatory effect on contact hypersensitivity
38. Shark-cartilage containing preparation protects cells against hydrogen peroxide induced damage and mutagenesis
39. Shark cartilage-containing preparation: Protection against reactive oxygen species
40. A comparison of shark cartilage and bovine cartilage
41. Media feeds frenzy over shark cartilage as cancer treatment
42. FDA takes action against firm marketing unapproved drugs
43. Control of tumor growth in animals by infusion of an angiogenesis inhibitor
44. Inhibition of angiogenesis by oral ingestion of powdered shark cartilage in a rat model
45. Effects of shark cartilage on mammary tumor neovascularization in vivo and cell proliferation in vitro
46. Demonstration of inhibitory effect of oral shark cartilage on basic fibroblast growth factor-induced angiogenesis in the rabbit cornea
47. Angiostatic and antitumoral activity of AE-941 (Neovastat®), a molecular fraction derived from shark cartilage
48. Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model
49. Effect of shark cartilage on tumor growth and survival time in
50. The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma
51. Boron neutron capture therapy of the rat 9L gliosarcoma: Evaluation of the effects of shark cartilage
52. [The national cancer fund (Koningin Wilhelmina Fonds) and the Houtsmuller-therapy for cancer]
53. Phase II study of AE-941 (Neovastat®; Shark Cartilage) in patients with early relapse or refractory multiple myeloma
54. Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without shark cartilage extract in treating patients who have stage III non-small cell lung removed by surgery
55. Phase III randomized study of AE-941 (Neovastat®; Shark Cartilage Extract) in patients with metastatic renal cell carcinoma refractory to immunotherapy
56. Rationale for a phase III clinical trial with AE-941 (Neovastat® (R)) in metastatic renal cell carcinoma patients refractory to immunotherapy
57. Angiogenesis antagonist as treatment for psoriasis: Phase I clinical trial results with AE-941 American
58. Shark cartilage extract tried as a novel psoriasis treatment
59. Phase I dose escalation study of AE-941, an antiangiogenic agent, in age-related macular degeneration patient
60. Antiinflammatory and analgesic activity of a water-soluble fraction from shark cartilage
61. The analgesic and antiinflammatory effects of shark cartilage are due to a peptide molecule and are nitric oxide (NO) system dependent